Mind Medicine (MindMed) Inc. (MNMD)

Market Cap	518.82M
Revenue (ttm)	n/a
Net Income (ttm)	-97.80M
Shares Out	73.33M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,501
Open	7.24
Previous Close	7.16
Day's Range	6.94 - 7.35
52-Week Range	3.49 - 12.22
Beta	2.38
Analysts	Strong Buy
Price Target	28.75 (+306.36%)
Earnings Date	Nov 7, 2024

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: MNMD
• Website: https://www.mindmed.co

Analyst Forecast

According to 9 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $28.75, which is an increase of 306.36% from the latest price.

Price Target

$28.75

(306.36% upside)

Analyst Consensus: Strong Buy